John Kapples - Insulet Senior Vice President General Counsel, Secretary

PODD Stock  USD 171.40  2.22  1.31%   

President

Mr. John W. Kapples is Senior Vice President, General Counsel, Secretary ince March 2019. From December 2015 to March 2019, he served as Vice President, Secretary and General Counsel at GCP Applied Technologies, Inc. From 2006 to August 2015, Mr. Kapples served as Vice President and Corporationrationrate Secretary of Covidien plc, which was acquired by Medtronic plc. in 2015. Prior to his role at Covidien, Mr. Kapples served in various roles of increasing responsibility at Raytheon Company, including Assistant General Counsel and Secretary, and he was a Corporationrationrate Associate at Sullivan Worcester LLP since 2019.
Age 64
Tenure 5 years
Address 100 Nagog Park, Acton, MA, United States, 01720
Phone978 600 7000
Webhttps://www.insulet.com
Kapples earned both his Bachelor of Arts in English and his Juris Doctor from Georgetown University. He is a member of the Massachusetts Bar Association and the Society of Corporationrationrationrate Secretaries & Governance Professionals.

Insulet Management Efficiency

The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.11. The current year's Return On Assets is expected to grow to 0.08. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Other Assets are forecasted to decline to 0.95.
The company currently holds 1.45 B in liabilities with Debt to Equity (D/E) ratio of 3.34, implying the company greatly relies on financing operations through barrowing. Insulet has a current ratio of 4.6, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Insulet until it has trouble settling it off, either with new capital or with free cash flow. So, Insulet's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Insulet sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Insulet to invest in growth at high rates of return. When we think about Insulet's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

PRESIDENT Age

Yaron ZilbermanMedigus Ltd ADR
42
Menashe SonnenscheinMedigus Ltd ADR
48
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. Insulet Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 2300 people. Insulet (PODD) is traded on NASDAQ Exchange in USA. It is located in 100 Nagog Park, Acton, MA, United States, 01720 and employs 3,000 people. Insulet is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Insulet Leadership Team

Elected by the shareholders, the Insulet's board of directors comprises two types of representatives: Insulet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Insulet. The board's role is to monitor Insulet's management team and ensure that shareholders' interests are well served. Insulet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Insulet's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Benjamin, Senior Vice President R&D, New Product Development and Commercialization
Sally Crawford, Lead Independent Director
John Fallon, Independent Director
Mark Field, Senior CTO
Laetitia Cousin, Quality Affairs
Deborah Gordon, Vice President Investor Relations and Corporate Communications
Daniel Levangie, Independent Director
James Mullen, Independent Director
John Kapples, Senior Vice President General Counsel, Secretary
Patrick Sullivan, CEO and President and Director
Wayde McMillan, CFO, Executive Vice President
Charles Liamos, Director of Advanced Technology and Director
Michael Levitz, CFO
Bradley Thomas, Executive VP of HR and Organizational Devel.
Charles Alpuche, Senior Vice President Global Manufacturing and Operations
David Lemoine, Independent Director
James Hollingshead, CEO President
Jessica Hopfield, Director
David Colleran, Vice President General Counsel
Brittany Bradrick, Vice President - Strategy and Corporate Development
Bret Christensen, Chief Commercial Officer
Deborah CPA, Vice Relations
Timothy Scannell, Director
Michael Minogue, Independent Director
Steven Sobieski, Independent Director
Aiman AbdelMalek, Senior Vice President Advanced Technology and Engineering
Corinne Nevinny, Independent Director
Regina Sommer, Independent Director
Mark Licari, Vice President - Global Manufacturing and Operations
Prem Singh, Senior Operations
Angela Wiczek, Senior Communications
Lauren Budden, Chief VP
Michael Spears, Senior Vice President Quality, Regulatory, and Clinical Affairs
Joseph Zakrzewski, Independent Director
Shacey Petrovic, Chief Commercial Officer
Trang Ly, Vice President and Medical Director

Insulet Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Insulet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Insulet using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.
Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Insulet Stock analysis

When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Global Correlations
Find global opportunities by holding instruments from different markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.043
Earnings Share
2.95
Revenue Per Share
24.331
Quarterly Revenue Growth
0.379
Return On Assets
0.0609
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.